Familial Hypercholesterolemia Clinical Trial
Official title:
Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is an autosomal codominant single gene disorder caused by
mutations in the LDL receptor gene (LDLR) that disrupt the normal clearance of LDL particles
from the plasma. Heterozygous patients (HeFH) present a two- to three-fold raise in plasma
LDL-cholesterol (LDL-C) concentrations and coronary artery disease occurs earlier among HeFH
carrying negative-receptor (NR) mutations as compared with HeFH subjects carrying
defective-receptor (DR) variants. Proprotein convertase subtilisin/kexin type 9 (PCSK9)
regulates LDL-C levels by binding to LDLR and by enhancing its intracellular degradation.
The objective of this study is to examine to what extent variations in LDL-C and Lipoprotein
(Lp) (a) concentrations are related to PCSK9 levels in a large French-Canadian cohort of
HeFH subjects.
The primary hypothesis is that that PCSK9 levels have a significant impact on LDL-C
concentration variability and are associated with Lp(a) levels.
n/a
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05284513 -
Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)
|
N/A | |
Enrolling by invitation |
NCT05271305 -
Pilot Study for a National Screening for Familial Hypercholesterolemia
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Not yet recruiting |
NCT00924339 -
Soy Food Intervention Trial
|
N/A | |
Withdrawn |
NCT00751608 -
Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients
|
Phase 2 | |
Terminated |
NCT00079846 -
Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy
|
Phase 2 | |
Completed |
NCT02624869 -
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
|
Phase 3 | |
Recruiting |
NCT05758779 -
The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial
|
N/A | |
Enrolling by invitation |
NCT04929457 -
Evaluation of a Digiphysical Screening Method to Identify and Diagnose Familial Hypercholesterolemia
|
||
Not yet recruiting |
NCT04455581 -
A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia
|
Phase 2 | |
Recruiting |
NCT04101149 -
Genetic Causes of Familial Hypercholesterolemia
|
||
Completed |
NCT00943306 -
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Completed |
NCT02462655 -
Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia
|
N/A | |
Terminated |
NCT00079859 -
Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
|
Phase 2 | |
Recruiting |
NCT05066932 -
Advanced Lipoproptein Profiling and Cardiovascular Risk Stratification in Familial Hypercholesterolemia
|
||
Not yet recruiting |
NCT04958629 -
A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population
|
||
Completed |
NCT02709850 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia
|
Phase 1 | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Terminated |
NCT02013713 -
French Observatory of Familial Hypercholesterolemia in Cardiology
|
||
Recruiting |
NCT02009345 -
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
|